Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ.
Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30.
Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS, Erickson BK, Shih IM, Fader AN.
Int J Gynecol Cancer. 2021 Aug;31(8):1165-1174. doi: 10.1136/ijgc-2021-002753. Epub 2021 Jul 1.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.
J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.
Lee EK, Liu JF.
Clin Adv Hematol Oncol. 2024 Jul-Aug;22(6):301-310.
HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM, Finkelman BS, Turner BM, Katerji H, Wang X, Varghese S, Wang T, Peng Y, Hicks DG, Zhang H.
Am J Clin Pathol. 2023 Oct 3;160(4):341-351. doi: 10.1093/ajcp/aqad056.
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
Lee EK, Fader AN, Santin AD, Liu JF.
Gynecol Oncol. 2021 Jan;160(1):322-332. doi: 10.1016/j.ygyno.2020.10.017. Epub 2020 Nov 5.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935. doi: 10.1158/1078-0432.CCR-20-0953. Epub 2020 Jun 29.
Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?
Crum CP, Yoon JY, Feltmate CM.
Gynecol Oncol. 2023 Feb;169:1-3. doi: 10.1016/j.ygyno.2022.11.019. Epub 2022 Nov 29.
Targeted Therapies in the Treatment of Uterine Serous Carcinoma.
Tymon-Rosario JR, Gorman M, Santin AD.
Curr Treat Options Oncol. 2022 Dec;23(12):1804-1817. doi: 10.1007/s11864-022-01030-7. Epub 2022 Nov 30.
Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.
Toboni M, Kurnit K, Erickson B, Powell M, Secord AA, Fader AN.
Int J Gynecol Cancer. 2025 Mar;35(3):101672. doi: 10.1016/j.ijgc.2025.101672. Epub 2025 Jan 30.
